BlinkLab secures A$17.5 million for diagnostic expansion. The ASX-listed biotech company raised oversubscribed capital at A$0.65 per share to accelerate FDA clearance for its autism diagnostic tool Dx1 and launch ADHD clinical trials using its Dx2 platform. The company has commenced its pivotal FDA 510(k) validation program with first participant enrollment completed. Morocco's government-funded nationwide autism screening initiative, launching April 2026, will deploy Dx1 across outpatient and hospital settings starting at 18 months of age, providing real-world validation data at no material capital cost to BlinkLab. The company targets FDA submission by end-2026 while advancing European CE marking and MDR processes. Directors committed A$200K in shares, signaling confidence in the dual-pronged diagnostic strategy targeting both autism and ADHD markets.
Post from MarketNews_en
Log in to interact with content.